Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eric A. Macklin, Ph.D.

Co-Author

This page shows the publications co-authored by Eric Macklin and Suma Babu.
Connection Strength

0.381
  1. Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020 02; 21(1-2):15-23.
    View in: PubMed
    Score: 0.210
  2. Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. Muscle Nerve. 2021 09; 64(3):309-320.
    View in: PubMed
    Score: 0.059
  3. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021 01; 63(1):31-39.
    View in: PubMed
    Score: 0.056
  4. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med. 2020 09 03; 383(10):919-930.
    View in: PubMed
    Score: 0.056
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.